NovaBridge Biosciences announced updated results from a Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) for patients with HER2-negative, first-line metastatic gastric cancer. The company reported that the most common givastomig-related treatment-related adverse events (TRAEs) were nausea, vomiting, and fatigue, with Grade 3 incidence at or below 11%. Immune-related gastritis was observed in 33% of patients in both dosing cohorts, with higher rates of Grade 3 gastritis at the 12 mg/kg dose compared to the 8 mg/kg dose. No Grade 5 TRAEs were reported. NovaBridge is preparing to initiate enrollment in a global, randomized Phase 2 study in the first quarter of 2026. Detailed Phase 1b dose expansion data are expected to be presented at a medical conference later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9620234) on January 06, 2026, and is solely responsible for the information contained therein.